Rate My Professor Kanneboyina Nagaraju

His research focuses on immunology, neuromuscular diseases, autoimmune diseases, and drug development, particularly translational research in autoimmune and genetic muscle diseases. With over 200 refereed publications and textbook chapters, notable works include "Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy" (2005, Journal of Experimental Medicine), "Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy" (2008, Neurobiology of Disease), "Immune-mediated pathology in Duchenne muscular dystrophy" (2015, Science Translational Medicine), and "Targeted disruption of the acid α-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II" (1998, Journal of Biological Chemistry). Nagaraju pioneered transgenic and knockout mouse models for muscle diseases, directed preclinical drug testing, and led efforts culminating in Vamorolone (AGAMREE), an FDA- and EMA-approved dissociated glucocorticoid for Duchenne muscular dystrophy. He has secured funding from NIH, U.S. Department of Defense, and foundations, holds 10 patents, and co-founded ReveraGen BioPharma and AGADA BioSciences. He contributes to scientific advisory boards, editorial boards, and international committees like TREAT-NMD.